Neurodegenerative disease management最新文献_第3页

Therapeutic strategies for Huntington's disease: current approaches and future direction. 亨廷顿舞蹈病的治疗策略：目前的方法和未来的方向。

IF 3.4

Neurodegenerative disease management Pub Date : 2026-04-01 Epub Date: 2025-08-28 DOI: 10.1080/17582024.2025.2552593

Mehak Gulzar, Sana Kauser, Sumaiya Khan, Mohd Adnan, Md Imtaiyaz Hassan

{"title":"Therapeutic strategies for Huntington's disease: current approaches and future direction.","authors":"Mehak Gulzar, Sana Kauser, Sumaiya Khan, Mohd Adnan, Md Imtaiyaz Hassan","doi":"10.1080/17582024.2025.2552593","DOIUrl":"10.1080/17582024.2025.2552593","url":null,"abstract":"Huntington's disease (HD) is an autosomal, progressive, dominant inherited neurological disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. HD is caused by abnormal expansion of trinucleotide CAG in exon1 of the Huntington gene and the accumulation of mutant huntingtin (mHTT) fragments, which leads to neurotoxicity mainly in the brain's cortex region. This review aimed to collect current research on developing effective treatment strategies, including small-molecule approaches, gene therapies, and protein degradation techniques to reduce the mHTT levels. We further discuss various therapeutic strategies, including CRISPR-based approaches and small-molecule targeted protein degradation. Additionally, the potential of VTX-003 and ANX005 in mitigating disease progression is explored. Despite these promising therapies, challenges persist, particularly in long-term assessment, delivery strategy, and off-target effects. Considering the future landscape and need, the review has strengthened the need of therapeutic interventions to enhance efficacy and safety, ultimately improving the quality of life of HD patients.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"209-223"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13011625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic symptoms, treatment patterns, and healthcare resource utilization in multiple system atrophy in the United States. 美国多系统萎缩的诊断症状、治疗模式和医疗资源利用。

IF 3.4

Neurodegenerative disease management Pub Date : 2026-04-01 Epub Date: 2025-09-07 DOI: 10.1080/17582024.2025.2554490

Sigal Kaplan, Handing Xie, Amit Kumar

{"title":"Diagnostic symptoms, treatment patterns, and healthcare resource utilization in multiple system atrophy in the United States.","authors":"Sigal Kaplan, Handing Xie, Amit Kumar","doi":"10.1080/17582024.2025.2554490","DOIUrl":"10.1080/17582024.2025.2554490","url":null,"abstract":"Background: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder with diverse symptoms that complicate diagnosis. We aimed to characterize MSA-related symptoms, medications, and healthcare resource utilization (HCRU).Research design and methods: This retrospective cohort study used a large US claims database. Newly diagnosed patients >30 years old with ≥2 MSA diagnosis (2017 - 2021) were matched to controls. Endpoints related to MSA symptoms, prescriptions, and HCRU were compared between the two groups during the first year after diagnosis. Conditional logistic regression models examined the association between each outcome and MSA.Results: A total of 1187 MSA patients and 4748 matched-controls were compared. MSA patients had significantly higher rates of various symptoms, respectively (OR and 95% CI): orthostatic hypotension (38.7% and 0.8%; 89.6, 57.3 - 140.2); memory disorders (22.4% and 3.6%; 9.2, 7.3 - 11.6); motor symptoms (78.1% and 33.1%; 7.5, 6.4 - 8.7); falls (11.1% and 2.2%; 6.4, 4.8 - 8.5); fatigue (46.6% and 13.6%; 5.8, 5.0 - 6.7); mood disorder (62.3% and 24.2%; 5.5, 4.8 - 6.4); and urinary dysfunction (30.8% and 9.1%; 4.9, 4.1 - 5.8), among other. They also received more medications for these conditions and had higher rates of hospitalizations and other HCRU.Conclusions: This real-world study of MSA-related symptoms, treatments, and HCRU demonstrates the significant disease burden associated with MSA.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"143-152"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13011585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145015813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the mid-term impact of telemonitoring in Parkinson's disease: insights from adoption into clinical practice. 探索远程监控在帕金森病中的中期影响：从采用到临床实践的见解。

IF 3.4

Neurodegenerative disease management Pub Date : 2026-04-01 Epub Date: 2025-10-15 DOI: 10.1080/17582024.2025.2562754

Foivos S Kanellos, Eleni Kosmidi, Georgios Rigas, Ermioni Petkou, Yannis V Simos, Lampros Lakkas, Dimitrios Peschos, Spyridon Konitsiotis, Konstantinos I Tsamis

{"title":"Exploring the mid-term impact of telemonitoring in Parkinson's disease: insights from adoption into clinical practice.","authors":"Foivos S Kanellos, Eleni Kosmidi, Georgios Rigas, Ermioni Petkou, Yannis V Simos, Lampros Lakkas, Dimitrios Peschos, Spyridon Konitsiotis, Konstantinos I Tsamis","doi":"10.1080/17582024.2025.2562754","DOIUrl":"10.1080/17582024.2025.2562754","url":null,"abstract":"Background: Routine clinical evaluations offer limited insight into daily variability and disease progression in Parkinson's disease (PD). While wearable devices are increasingly used to improve patient monitoring, evidence of their effectiveness remains scarce.Objective: To assess the efficacy of integrating a telemonitoring system into standard clinical procedures, highlighting its role in enabling efficient, patient-centered treatment adjustments.Methods: Thirty-five PD patients were monitored for 6 months using a telemonitoring device alongside standard care. Disease progression was assessed via MDS-UPDRS part III (UPDRS-p3) and device-reported outcomes (dUPDRS) at baseline and follow-up. Physicians provided feedback on telemedicine utility.Results: UPDRS-p3 scores improved by 1.9-5.63 points. Changes in UPDRS-p3 strongly correlated with dUPDRS (r = 0.82). Sixty-two percent of patients had treatment modifications, 36% of which occurred remotely.Conclusion: Telemonitoring supported clinical decisions, detected subtle symptom changes, and offered valuable insights for improving motor symptoms and patient management.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"135-141"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13011622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145293176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of region-based shape alterations in MRI as indicators of Parkinson's Disease. MRI中基于区域的形状改变作为帕金森病指标的影响

IF 3.4

Neurodegenerative disease management Pub Date : 2026-03-26 DOI: 10.1080/17582024.2026.2647108

Komal Singh, Ashish Khare

{"title":"Impact of region-based shape alterations in MRI as indicators of Parkinson's Disease.","authors":"Komal Singh, Ashish Khare","doi":"10.1080/17582024.2026.2647108","DOIUrl":"https://doi.org/10.1080/17582024.2026.2647108","url":null,"abstract":"Background: Parkinson's Disease (PD) is a neuro-degenerative condition that progressively impairs movement, resulting from the loss of dopamine-producing brain cells. Early detection of such a condition helps slowing their progression and allows more effective management of the disease.Materials and methods: MRIs are the most common type of imaging technique used for detection of PD without any specific risk to patients. Therefore, in this study, a novel MRI-based method has been proposed to identify structural biomarkers of certain regions within the brain for the detection of PD. The objective of this study is to analyze the alterations in geometrical shapes of the different regions of the brain in PD. The study involves segmentation of six regions of interest in analysis and identification of their geometrical shapes in PD. Several statistical analyses have been performed on the segmented regions to show the most pronounced shape alterations in PD. Further, a geometrical feature-based classification model is subsequently used to validate these findings.Results: The proposed method achieved good accuracy, surpassing several cutting-edge approaches.Conclusion: The results indicate that pinpointing key regions for PD detection may aid early PD detection with low computational cost and reveal subtle brain changes invisible to the human eye.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-11"},"PeriodicalIF":3.4,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147521417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring maintenance of spatiotemporal gait parameters during internal and external rhythmic auditory cueing in Parkinson's disease. 探索帕金森病患者内外节律性听觉提示过程中步态参数的时空维持。

IF 3.4

Neurodegenerative disease management Pub Date : 2026-03-25 DOI: 10.1080/17582024.2026.2647109

Allison M Haussler, Sidney T Baudendistel, Elinor C Harrison, Lauren E Tueth, Kerri S Rawson, Gammon M Earhart

{"title":"Exploring maintenance of spatiotemporal gait parameters during internal and external rhythmic auditory cueing in Parkinson's disease.","authors":"Allison M Haussler, Sidney T Baudendistel, Elinor C Harrison, Lauren E Tueth, Kerri S Rawson, Gammon M Earhart","doi":"10.1080/17582024.2026.2647109","DOIUrl":"https://doi.org/10.1080/17582024.2026.2647109","url":null,"abstract":"Introduction: Rhythmic auditory cueing is a well-researched intervention to address gait impairment in Parkinson's disease (PD). Both external and internal music-based cues improve spatiotemporal gait variables. However, less is known about individuals' ability to maintain rhythm and stabilize gait within cued walking bouts, which is critical for real-world application.Methods: Two samples of individuals with PD completed 30-s (n = 100) and 3min (n = 30) gait trials; one uncued and two cued conditions set at 120% preferred cadence: Music (external) and Mental (internal). APDM sensors measured gait variables. Data were binned and repeated-measures ANOVAs assessed effects of cue condition and time on velocity, stride length, cadence, and coefficients of variation (CV) within a trial, focusing on the beginning and end.Results: Both cues led to significant increases in velocity and cadence compared to uncued walking. Small but statistically significant gait decrements occurred within both 30-s and 3-min walking assessments. Generally, mental cues resulted in longer strides, while Music cues led to higher cadence, suggesting differences in strategy to match cue.Conclusions: Re-presenting the cue, using more moderate cues, or implementing adaptive cueing may be beneficial to address potential gait decrements during cued walks. Future research should explore strategy differences to optimize cue-based gait training.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-13"},"PeriodicalIF":3.4,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147513162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pilot randomized controlled trial of the ReFresh online fatigue management programme for people with Parkinson's disease. 针对帕金森病患者的ReFresh在线疲劳管理程序的试点随机对照试验。

IF 3.4

Neurodegenerative disease management Pub Date : 2026-03-23 DOI: 10.1080/17582024.2026.2647107

Sarah Alageel, Jane Hibberd, Katherine H O Deane

{"title":"Pilot randomized controlled trial of the ReFresh online fatigue management programme for people with Parkinson's disease.","authors":"Sarah Alageel, Jane Hibberd, Katherine H O Deane","doi":"10.1080/17582024.2026.2647107","DOIUrl":"https://doi.org/10.1080/17582024.2026.2647107","url":null,"abstract":"Aims: Fatigue is one of the most disabling symptoms experienced by people with Parkinson's disease, yet few evidence-based non-pharmacological interventions are available. This study evaluated the feasibility, acceptability, and exploratory clinical signals of the Rebalancing Fatigue and Enhancing Self-Help (ReFresh) online fatigue management programme for people with Parkinson's disease.Patients and methods: A pilot randomized controlled trial with a wait-list control group was conducted. Participants with Parkinson's disease experiencing fatigue were randomized to either the six-week ReFresh online programme or a wait-list control. Feasibility outcomes included recruitment, retention, adherence, and participant engagement. Secondary outcomes included fatigue severity, fatigue self-efficacy, sleep quality, mood, and occupational performance.Results: A total of 118 participants were randomized. Recruitment targets were achieved; however, retention and adherence were modest. Participants who completed the programme reported improvements in fatigue self-efficacy and perceived ability to manage fatigue, while changes in fatigue severity were smaller. Qualitative feedback indicated that participants valued the flexibility and accessibility of the online format.Conclusions: The ReFresh programme demonstrated feasibility and acceptability as a digitally delivered fatigue management intervention for people with Parkinson's disease. Future research should explore strategies to improve engagement and evaluate the programme in a fully powered randomized controlled trial.Clinical trial registration: ISRCTN Registry, ISRCTN62114944, https://www.isrctn.com/ISRCTN62114944.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-9"},"PeriodicalIF":3.4,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Portuguese consensus for the use of cladribine tablets in multiple sclerosis. 葡萄牙一致同意使用克拉德滨片治疗多发性硬化症。

IF 3.4

Neurodegenerative disease management Pub Date : 2026-03-23 DOI: 10.1080/17582024.2026.2647105

João de Sá, Mariana Santos, Sónia Batista

{"title":"Portuguese consensus for the use of cladribine tablets in multiple sclerosis.","authors":"João de Sá, Mariana Santos, Sónia Batista","doi":"10.1080/17582024.2026.2647105","DOIUrl":"10.1080/17582024.2026.2647105","url":null,"abstract":"Aims: Multiple sclerosis (MS) is a chronic immune-mediated neurodegenerative disease. Cladribine tablets, an immune reconstitution therapy, are approved for the treatment of highly active relapsing-remitting MS (RRMS). Evidence on how to manage patients, particularly beyond the fourth year after treatment initiation, is scarce. This study aimed to formulate recommendations to guide cladribine treatment in MS patients.Materials and methods: Delphi methodology was followed with the participation of 33 Portuguese neurologists. Statements regarding treatment schemes, selection of patients, treatment decisions, assessment and monitoring, safety recommendations, and family planning were voted on. Consensus was obtained when ≥80% of experts agreed on a five-point scale.Results: Consensus was obtained for 50% of the statements. Experts were unanimous in stating that MS patients should start treatment as soon as possible after diagnosis and that treatment decisions should be based on a personalized approach. Experts defined criteria for patient selection, additional cladribine cycles, and therapy switching. Experts also defined monitoring schedules, treatment assessments, safety recommendations, and family planning.Conclusions: This study guides the use of cladribine tablets in clinical practice, supporting treatment decision-making in patients with RRMS, and summarizes the current knowledge from clinical trials and real-world studies of the efficacy and safety of cladribine tablets.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-8"},"PeriodicalIF":3.4,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Registered Dietitians' perspectives on nutrition management of persons living with amyotrophic lateral sclerosis. 注册营养师对肌萎缩侧索硬化症患者营养管理的看法。

IF 3.4

Neurodegenerative disease management Pub Date : 2026-03-19 DOI: 10.1080/17582024.2026.2646759

Amy C Ellis, Stephanie Dobak, Keith Pearson, Rebekah McGuire, Tyler Sutton

{"title":"Registered Dietitians' perspectives on nutrition management of persons living with amyotrophic lateral sclerosis.","authors":"Amy C Ellis, Stephanie Dobak, Keith Pearson, Rebekah McGuire, Tyler Sutton","doi":"10.1080/17582024.2026.2646759","DOIUrl":"https://doi.org/10.1080/17582024.2026.2646759","url":null,"abstract":"Aim: Persons with amyotrophic lateral sclerosis (PALS) are at high risk for malnutrition, which is a negative prognostic factor for disease progression and survival. This study explored the perspectives of Registered Dietitians (RDs) providing nutrition care to PALS, focusing on barriers and facilitators to optimal patient care.Methods: RDs from U.S. multidisciplinary ALS clinics participated in six virtual focus groups. Recordings were transcribed verbatim and independently coded by two researchers for deductive content analysis.Results: RDs highlighted the importance of using clinical judgment to assess nutrition status and individualizing recommendations to respect patient autonomy. The multidisciplinary team model was identified as a strong facilitator to optimal patient care, while insurance coverage for nutrition-related supplies was a common barrier. RDs reported having little prior knowledge of ALS before assuming their current roles and described the need to upskill through self-teaching and on-the-job experience.Conclusions: Results emphasize the importance of clinical judgment with respect to patient autonomy in providing nutrition care to PALS. The barriers and facilitators identified across multiple levels provide insight for future interventions to improve patient care.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-9"},"PeriodicalIF":3.4,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147486370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasma proteomic trajectories before the onset of neurodegenerative diseases. 神经退行性疾病发病前的血浆蛋白质组学轨迹。

IF 3.4

Neurodegenerative disease management Pub Date : 2026-03-19 DOI: 10.1080/17582024.2026.2646760

Zhihan Zhang, Rui Fan, Sisi Jing, Shiyi Liu, Linqi Liu, Wenjun Que, Dan Lu, Yaoqi Gan, Fei Xiao

引用次数: 0

Burden of Parkinson's disease from 1990 to 2021 at the global, regional, and national level, with forecasts to 2035. 1990 - 2021年全球、区域和国家层面的帕金森病负担，并预测到2035年。

IF 3.4

Neurodegenerative disease management Pub Date : 2026-03-17 DOI: 10.1080/17582024.2026.2645616

Sibo Huang, Jialin Wu, Gerun Chen, Yuefei Liang, Zhiguo Chen, Jun Xia, Wenjie He

{"title":"Burden of Parkinson's disease from 1990 to 2021 at the global, regional, and national level, with forecasts to 2035.","authors":"Sibo Huang, Jialin Wu, Gerun Chen, Yuefei Liang, Zhiguo Chen, Jun Xia, Wenjie He","doi":"10.1080/17582024.2026.2645616","DOIUrl":"https://doi.org/10.1080/17582024.2026.2645616","url":null,"abstract":"Background: Parkinson's disease (PD) poses a growing global health challenge. Our study systematically assessed the global, regional, and national burden of PD from 1990 to 2021 and projected trends to 2035.Methods: This study utilized data from the Global Burden of Disease (GBD) 2021 to systematically analyze the global, burden of PD from 1990 to 2021 and project trends up to 2035. By integrating prevalence, mortality, and disability-adjusted life years (DALY) metrics, alongside Socio-Demographic Index (SDI), we employed the Bayesian age-period-cohort (BAPC) model and decomposition analysis to assess drivers of PD burden.Results: From 1990 to 2021, the prevalence of PD increased by 273.75%, mortality increased by 162.17%. In terms of regions, the low-middle SDI regions had the highest average annual percentage changes (EAPC) in prevalence, mortality, which were 4.57%, 2.51%, respectively. Projections from 2022 to 2035 suggest that the prevalence will continue to rise, while mortality is expected to decline.Conclusions: The global burden of PD exhibits a persistent upward trajectory. This is particularly noticeable among middle-aged and elderly men, as well as in regions with the low-middle SDI. Targeted measures to address regional healthcare gaps and to improve global aging are crucial for mitigating the burden of PD.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-13"},"PeriodicalIF":3.4,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147474687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0